Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.
Your view on PLX
Overview
What the company does, where it operates, and who runs it.
About Protalix BioTherapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dror Bashan
- Headquarters
- 2 University Plaza, Hackensack, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dror Bashan
- Headquarters
- 2 University Plaza, Hackensack, NJ, US
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
The company offers Elelyso for the treatment of Gaucher disease.
Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Protalix BioTherapeutics, Inc., and the rating behind it. PLX last traded at $2.64, 11.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Protalix BioTherapeutics, Inc.. Starting points for Protalix BioTherapeutics, Inc.: P/E 11.0, EPS $0.24, beta 0.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Protalix BioTherapeutics, Inc.. Protalix BioTherapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Protalix BioTherapeutics, Inc.. Trailing twelve-month EPS for Protalix BioTherapeutics, Inc. stands at $0.24. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Protalix BioTherapeutics, Inc.. Protalix BioTherapeutics, Inc. has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Protalix BioTherapeutics, Inc. valued side by side against its closest peers. Protalix BioTherapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Protalix BioTherapeutics, Inc., and how their positions are changing. At a $212.7M market value, institutional positions materially move Protalix BioTherapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Protalix BioTherapeutics, Inc. executives and directors. Shares of Protalix BioTherapeutics, Inc. have traded between $1.32 and $3.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Protalix BioTherapeutics, Inc.. Protalix BioTherapeutics, Inc. is a $212.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Protalix BioTherapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Protalix BioTherapeutics, Inc.. Coverage tracks Protalix BioTherapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.